In this context, the discovery of immune checkpoints like cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death/ligand 1 (PD-1/PD-L1) has enabled the development of immune checkpoint inhibitors (ICIs), antibodies that target these checkpoints for the treatment of cancer [4]. This evidence concerns the gene CTLA4 and cancer.